rhG-CSF对急性淋巴细胞白血病缓解期患者化疗所致白细胞减少的预防作用

The role of recombinant human granulocyte-colony stimulating factor(rhG-CSF)against neutropenia caused by HD-MTX chemotherapy for acute lymphocytic leukemia(ALL)

目的 观察重组人粒细胞集落刺激因子 (rh G- CSF)对急性淋巴细胞白血病 (AL L )缓解期患者大剂量甲氨蝶呤 (HD-MTX)治疗所致白细胞减少的预防作用。方法 12例 AL L 缓解期患者共接受 HD- MTX化疗 34周期 ,随机分成 3组 ,A组 (对照组 )、B组 (化疗后给予 rh G- CSF2μg/ kg皮下注射 ,d2～ 1 1 )和 C组 (化疗后给予 rh G- CSF5μg/ kg皮下注射 ,d2～ 1 1 )。结果 B组和 C组 3～ 4度白细胞减少的发生率较低 ,且两组白细胞减少程度均较 A组轻 (P<0 .0 1) ,但 B组和 C组间无明显差异 (P>0 .0 5 )。结论 小剂量 rh G- CSF可以防治 AL L 缓解期患者 HD-

Objective To observe the efficacy of rhG-CSF against HD-MTX induced neutropenia in ALL.Methods Twelve patients with ALL receiving total 34 cycles of HD-MTX(3～5 g/m 2) were randomly divided to receive respectively chemotherapy(group A) and subcutaneous injection of 2 μg/kg and 5 μg/kg rhG-CSF during d 2～11 in combination with chemotherapy(group B and C).Results The occurrence of toxicity criteria grade 3～4 neutropenia was less in the rhG-CSF group B and C.The degree of neutropenia in both groups was milder than control group(group A)(P<0.01),but there was no significant statistical difference between group B and C(P>0.05).Conclusion The addition of rhG-CSF to HD-MTX chemotherapy in patients with ALL can reduce the incidence of grade 3～4 neutropenia.